Pura Vida Investments’s Aclaris Therapeutics ACRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-48,266
Closed -$702K 228
2021
Q4
$702K Buy
+48,266
New +$731K 0.03% 197
2021
Q2
Sell
-175,799
Closed -$4.43M 220
2021
Q1
$4.43M Buy
175,799
+125,799
+252% +$2.46M 0.13% 125
2020
Q4
$324K Buy
+50,000
New +$211K 0.01% 172

Other funds holding ACRS

Pura Vida Investments's ACRS Position: Q1 2022 in Review

Pura Vida Investments sold out of Aclaris Therapeutics (ACRS) in Q1 2022, closing a stake of 48,266 shares — an estimated $702K sold.

Pura Vida Investments first reported a position in ACRS in Q4 2020 and held it in 3 quarters. The position peaked at $4.43M in Q1 2021. 109 funds tracked by Wall St. Rank hold ACRS as of Q1 2022.

  • Pura Vida Investments reported no remaining Aclaris Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Pura Vida Investments sold 48,266 Aclaris Therapeutics shares in Q1 2022, an estimated $702K.
  • Pura Vida Investments first reported a position in Aclaris Therapeutics in Q4 2020 and held it in 3 quarters.
  • Pura Vida Investments's Aclaris Therapeutics position peaked at $4.43M in Q1 2021.
  • 109 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2022.

Based on Pura Vida Investments's 13F filing for Q1 2022, filed 16 May 2022.